Medical Condition

kidney cancer

Total Trials

15

Recruiting Now

15

Trial Phases

Phase 4, Phase 1, Phase 2, Phase 1

Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.

Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.

The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.

Frequently Asked Questions — kidney cancer Clinical Trials

How many clinical trials are currently recruiting for kidney cancer?

ClinicalMetric currently tracks 15 actively recruiting clinical trials for kidney cancer, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 15. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for kidney cancer?

kidney cancer research spans Phase 1 (2 trials), Phase 2 (4 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a kidney cancer clinical trial?

Eligibility criteria for kidney cancer trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 4

Top Sponsors

Chad R. Tracy 1 trial

University of Aarhus 1 trial

Sheffield Teaching Hospitals NHS Foundation Trust 1 trial

University Hospital, Bordeaux 1 trial

University of Cambridge 1 trial

kidney cancer

Frequently Asked Questions — kidney cancer Clinical Trials

Recruiting Clinical Trials

Preop Laxatives in Robotic Urologic Surgery

FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis

Ex VIvo DEtermiNed Cancer Therapy

Rein 3D PRINT MECHANICS

Investigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Renal Cancer Detection Using Convolutional Neural Networks

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

A Study of VET3-TGI in Patients With Solid Tumors

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Ivonescimab in the Treatment of Multiple Advanced Tumors

Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

Protocol Active Surveillance Small Renal Masses (SRMs)

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus